(Bloomberg) -- Eli Lilly & Co. has signed a deal with the AI startup Profluent Inc. worth up to $2.25 billion to find new ways to edit DNA, the company’s latest bet that artificial intelligence can ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ali Madani, PhD, CEO of Profluent, says there’s an urgent need to move away from the time-consuming slog of random therapeutic discovery and into artificial intelligence (AI)-based bespoke design.

Collaboration combines Profluent's frontier AI platform with Lilly's leading capabilities in genetic medicines AI-designed recombinases aim to unlock kilobase-scale DNA editing capabilities across ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly (LLY.N), opens new tab worth up ‌to $2.25 billion to develop ...

Last year, Salesforce, the company best known for its cloud sales support software (and Slack), spearheaded a project called ProGen to design proteins using generative AI. A research moonshot, ProGen ...

California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that will focus on gene-editing therapies. Profluent has attracted attention ...

Profluent has raised $106 million to scale up use of its AI models for biology in drug development and agriculture. Ali Madani started thinking about how AI could be programmed for biology in 2020, ...

Jeff Bezos has had quite a busy week, having just concluded his third venture capital investment in a promising artificial intelligence startup. This time, the recipient of Bezos’s largesse is a ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions ...